Israel Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Israeli Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 14.6%, reaching USD 28.3 million in 2031 from USD 14.3 million in 2026.

Key Highlights

Market Overview

The market structure reflects a mix of public reimbursement influence and multinational device supplier concentration. Abbott, Dexcom, and Medtronic account for most installed CGM systems, supported by established distribution networks and integration with insulin delivery platforms. Israeli digital health firms contribute to adjunct solutions, including data platforms and remote monitoring tools, but core sensor and transmitter supply remains externally sourced.

Buyer behavior is shaped by clinical outcomes, device reliability, interoperability with insulin pumps, and long-term sensor cost. Hospitals and specialist clinics initiate therapy, but ongoing use has shifted toward home care settings where patients and caregivers rely on real-time alerts and mobile-based glucose tracking. Diagnostic centers play a supporting role in calibration, follow-up, and treatment adjustments.

Between 2026 and 2031, procurement decisions are expected to remain tightly linked to reimbursement eligibility, clinical guidelines, and supplier contracting with Israel’s health maintenance organizations. Expansion of use beyond insulin-dependent populations depends on pricing adjustments and broader coverage definitions, particularly for early-stage type 2 diabetes management and preventive monitoring.

Key Market Indicators

Market Drivers

Expansion of insulin-dependent diabetes cohorts under clinical monitoring protocols.

Clinical diabetes management in Israel prioritizes intensive monitoring for type 1 diabetes and complex insulin-dependent cases. CGM systems are prescribed to reduce hypoglycemia risk and improve glycemic stability, particularly in patients with documented recurrent low-glucose events. Reimbursement eligibility tied to clinical thresholds ensures steady baseline demand. Hospitals and endocrinology clinics act as gatekeepers, standardizing adoption within defined patient pathways. This structure supports recurring procurement of sensors and transmitters rather than one-time device purchases, reinforcing predictable replacement cycles.

Integration of CGM with insulin pump therapy in advanced diabetes care.

Insulin pump adoption creates direct linkage demand for CGM sensors that enable automated insulin delivery systems. Medtronic’s integrated systems and cross-compatibility initiatives across global manufacturers have strengthened CGM utilization in pump-dependent patients. Clinical preference for closed-loop or semi-automated insulin delivery increases sensor usage intensity per patient. This raises recurring consumption of consumables, particularly in hospital-supervised initiation phases followed by home-based continuation. The driver affects supplier revenue stability through recurring sensor replacement cycles rather than capital device sales.

Shift toward home-based glucose monitoring and outpatient chronic care.

Health system pressure to reduce hospital dependency has increased outpatient diabetes management in Israel. CGM devices support remote monitoring, allowing clinicians to adjust therapy without frequent hospital visits. This reduces clinical workload while increasing patient responsibility for daily monitoring. Home care providers and digital health platforms increasingly act as intermediaries for data interpretation. The shift increases device utilization frequency per patient and strengthens demand for user-friendly, app-connected CGM systems with simplified calibration and alert functions.

Broader clinical acceptance of CGM for high-risk non-critical patients.

Clinical guidelines have gradually extended CGM use beyond severe insulin-dependent cases to include pregnancy-related diabetes and unstable glycemic profiles. This creates incremental demand outside traditional type 1 cohorts. However, adoption remains tightly regulated through reimbursement criteria. Expansion in this segment is gradual and policy-dependent, with insurers evaluating cost offsets from reduced hospital admissions and complication rates.

Market Restraints and Challenges

Reimbursement eligibility limits for type 2 diabetes expansion.

CGM access in Israel remains concentrated in defined clinical categories, restricting wider adoption among type 2 diabetes patients not using intensive insulin therapy. While clinical benefits are recognized, reimbursement frameworks prioritize high-risk groups with documented hypoglycemia or pregnancy-related complications. This creates uneven adoption across patient populations. Suppliers face slower volume expansion despite strong clinical acceptance. Expansion depends on payer willingness to fund preventive monitoring, which remains under evaluation in terms of long-term cost savings.

High recurring cost of sensor replacement cycles.

CGM systems require continuous sensor replacement, creating recurring expenditure burdens for health funds and patients outside fully reimbursed categories. Even when partially subsidized, cumulative annual costs remain significant compared to traditional glucose test strips. Health maintenance organizations apply strict utilization controls to manage budget exposure. This affects prescription volume and encourages selective allocation. Manufacturers face pricing pressure during contract negotiations with national payers, limiting margin expansion despite rising demand.

Device interoperability and system integration constraints.

Integration between CGM devices and insulin delivery systems varies across manufacturers, limiting seamless adoption of closed-loop solutions. Hospitals often prefer standardized systems to reduce training and maintenance complexity. However, interoperability gaps require additional configuration and patient training. This increases onboarding time and slows large-scale deployment. Suppliers must invest in compatibility programs and software updates to maintain clinical relevance, particularly in institutional procurement environments.

Clinical training and adherence variability among patients.

Effective use of CGM devices depends on patient engagement, consistent wear, and correct interpretation of glucose data. Variability in adherence reduces clinical effectiveness and complicates physician reliance on CGM-generated insights. Education programs are required to ensure correct usage, particularly during early adoption phases. Health providers bear additional training costs, and inconsistent usage can lead to underutilization of device capabilities, affecting perceived value in payer evaluations.

Major Segment Analysis

Home Care

Home care represents the most commercially active end-user environment for CGM in Israel, driven by chronic disease management outside hospital settings. Patients with type 1 diabetes and selected insulin-dependent type 2 cohorts increasingly rely on real-time monitoring to manage daily glucose fluctuations. Device usage shifts responsibility from clinical institutions to individuals, supported by mobile applications and remote physician oversight.

Adoption in this segment is shaped by usability, alert accuracy, and sensor lifespan rather than institutional procurement standards. Patients prioritize ease of application and minimal calibration requirements. Manufacturers compete on user experience, data visualization, and integration with insulin dosing tools. Cost sensitivity remains present, but clinical benefit and convenience often outweigh price considerations within reimbursed populations.

Home care expansion is constrained by reimbursement limits and patient training requirements. Despite strong clinical endorsement, full market penetration depends on payer coverage policies and sustained adherence. However, recurring sensor consumption in this segment creates predictable revenue streams for suppliers, making home care the primary driver of long-term CGM utilization growth in Israel.

Competitive Landscape

The CGM market in Israel is structured around a small number of global medical device manufacturers supplying nationally reimbursed healthcare systems. Abbott Laboratories, Dexcom, and Medtronic dominate installed base volumes through established clinical relationships, broad product portfolios, and integration with insulin delivery systems. Competition is shaped less by price alone and more by reimbursement listing status, clinical validation, and compatibility with hospital workflows.

Local companies such as GlucoMe and OrSense focus on digital monitoring, non-invasive sensing concepts, and adjunct platforms rather than high-volume disposable sensors. Their role remains supportive, often aligned with remote care and data analytics rather than primary CGM hardware supply. Barriers to entry remain high due to clinical validation requirements, procurement centralization, and long qualification cycles.

Competition increasingly centers on ecosystem integration, including software platforms, remote monitoring capabilities, and interoperability with insulin pumps. Suppliers invest in payer engagement and clinical evidence generation to maintain reimbursement positioning.

Recent Developments

• December 2025: Medtronic commercially launched the MiniMed 780G system integrated with Abbott's Instinct CGM sensor in the United States. The collaboration strengthens Medtronic's global diabetes portfolio and supports future adoption in markets such as Israel through its international distribution network.

• September 2025: Senseonics announced an agreement to assume direct commercialization of the Eversense 365 implantable CGM from Ascensia Diabetes Care in the United States. The transaction strengthens the company's commercial position and supports future international expansion opportunities, including Israel.

• September 2025: Medtronic received U.S. FDA clearance for MiniMed 780G integration with Abbott's Instinct CGM sensor and expanded Type 2 diabetes indications. The approval enhances Medtronic's interoperable CGM ecosystem, supporting broader global commercialization, including markets served through Israel.

• April 2025: Senseonics and Sequel Med Tech announced integration of the twiist automated insulin delivery system with the Eversense 365 implantable CGM. The collaboration advances long-term CGM-enabled diabetes management technologies that could reach additional international markets over time.

Regulatory and Policy Environment

CGM access in Israel is structured through national health insurance frameworks that define eligibility based on clinical severity, hypoglycemia risk, and patient category. Type 1 diabetes patients and selected high-risk groups receive coverage under established criteria, while broader preventive use remains limited. Reimbursement rules are enforced through health maintenance organizations that control procurement volumes and device allocation.

Regulatory oversight focuses on medical device approval alignment with international standards, particularly European certifications. The Ministry of Health plays a central role in determining reimbursement expansion, balancing clinical benefit with budget impact. Policy discussions increasingly evaluate CGM use in early-stage diabetes management, but cost-effectiveness evidence remains central to any expansion decisions.

Outlook and Strategic Implications (2026–2031)

CGM demand in Israel is expected to remain structurally tied to reimbursement policy rather than open-market consumer adoption. Expansion will likely come from incremental broadening of eligible patient groups rather than a shift in funding model. Suppliers that align closely with national health funds and demonstrate clinical and economic value will retain stronger positioning.

Manufacturers face increasing pressure to support interoperability with insulin delivery systems and reduce total cost per patient per year. Digital health integration, particularly remote monitoring platforms, will become a key differentiator in hospital procurement decisions. Home care will remain the primary utilization channel, reinforcing recurring sensor consumption as the central revenue driver.

Over the forecast period, competitive advantage will depend on payer engagement, clinical evidence generation, and ecosystem integration rather than device specification alone.

Israel Continuous Glucose Monitoring Market Scope: